Erythropoietin claims monitoring policy: implications for clinical practice.
The revised erythropoietin claims monitoring policy that will govern reimbursement by the Centers for Medicare & Medicaid Services for Epoettin alfa and darbepoetin alfa administered to patients on dialysis takes effect on April 1, 2006. The new policy provides several significant improvements that should enhance clinicians' ability to manage anemia rationally. However, several aspects of the new policy are ambiguous and will require further clarification and ongoing evaluation to determine the effect on practice patterns and clinical outcomes.
Messana
Tony
T
St. Joseph Hospital Renal Services, Orange, CA, USA.
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D014487:Centers for Medicare and Medicaid Services, U.S. / Q000458:organization & administration; D000068256:Darbepoetin alfa; D004282:Documentation; D016527:Drug Costs; D004363:Drug Utilization; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000191:economics*; D006397:Hematinics / Q000191:economics*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007344:Insurance Claim Reporting / Q000592:standards*; D007676:Kidney Failure, Chronic / Q000150:complications; D016134:Organizational Policy; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D012051:Reimbursement Mechanisms / Q000458:organization & administration*; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors; D017749:Total Quality Management / Q000458:organization & administration; D014481:United States
D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa